Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation.

Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Abstract Text:

    yuki asano-moriYuki Asano-Mori,yoshinobu kandaYoshinobu Kanda,kumi oshimaKumi Oshima,shinichi kakoShinichi Kako,akihito shinoharaAkihito Shinohara,hideki nakasoneHideki Nakasone,hiroyuki satoHiroyuki Sato,takuro watanabeTakuro Watanabe,noriko hosoyaNoriko Hosoya,koji izutsuKoji Izutsu,takashi asaiTakashi Asai,akira hangaishiAkira Hangaishi,toru motokuraToru Motokura,shigeru chibaShigeru Chiba,mineo kurokawaMineo Kurokawa,

    Late cytomegalovirus (CMV) disease beyond day 100 after hematopoietic stem cell transplantation (HSCT) has become an increasing problem after the introduction of preemptive ganciclovir (GCV) administration. To clarify the risk factors and outcome for late CMV reactivation and disease, we retrospectively analyzed the records of 101 Japanese adult patients who underwent allogeneic HSCT between 1998 and 2005 at our hospital. Fifty-one developed late positive CMV antigenemia, with a cumulative incidence of 53%. Recipient CMV seropositivity, the use of alemtuzumab, chronic GVHD, and high-dose steroids were significantly associated with late positive antigenemia. Eight patients developed late CMV disease, with a cumulative incidence of 8%, including retinitis and gastrointestinal disease. None progressed to a fatal disease. The use of alemtuzumab was identified as an independent significant risk factor for late CMV disease, although it was not associated with increased non-relapse mortality. Among the 51 patients with late positive antigenemia, 28 had consistently less than three positive cells, 25 of whom showed negative conversion without antiviral agents. In conclusion, late CMV antigenemia appeared to develop frequently, especially in patients with profound immune suppression; however, a fatal outcome could be prevented by optimal preemptive therapy. Low-level antigenemia may not require antiviral treatments.

    Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Publishing Authors By Initials

    y asano-moriY Asano-Mori,y kandaY Kanda,k oshimaK Oshima,s kakoS Kako,a shinoharaA Shinohara,h nakasoneH Nakasone,h satoH Sato,t watanabeT Watanabe,n hosoyaN Hosoya,k izutsuK Izutsu,t asaiT Asai,a hangaishiA Hangaishi,t motokuraT Motokura,s chibaS Chiba,m kurokawaM Kurokawa,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: International journal of hematology

    VOLUME: 87

    Page Numbers: 310-8

    Journal Abbreviation: Int. J. Hematol.

    ISSN: 0925-5710

    DAY: 5

    MONTH: 03

    YEAR: 2008

    Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9111627

    Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation.

    AFFILIATION: Department of Hematology & Oncology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Int J Hematol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News